Substance / Medication

Bedaquiline

Overview

Active Ingredient
bedaquiline
RxNorm CUI
1364504

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Cheraghi Mahdis, Amiri Mehrnaz, Andarzgoo Sahar et al. · J Bras Pneumol · 2025
PMID: 40172415Meta-AnalysisFull text (PMC)
Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
Fekadu Ginenus, Tolossa Tadesse, Bekele Firomsa et al. · BMJ Glob Health · 2025
PMID: 40194835Meta-AnalysisFull text (PMC)
Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis.
Al Omar Mohamad Faisal Said, Alchikhsuliman Izz Eddin Majed, Awad Sondos Mahmoud et al. · Int J Mycobacteriol · 2025
PMID: 41411378Meta-Analysis
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.
Silva Denise Rossato, Fernandes Flávia Fonseca, Ferreira Juliana Carvalho et al. · J Bras Pneumol · 2025
PMID: 39813501Meta-AnalysisFull text (PMC)
Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis.
Hu Xinyang, Wu Zhiwei, Lei Jing et al. · BMC Infect Dis · 2025
PMID: 40355818Meta-AnalysisFull text (PMC)
Population pharmacokinetics of bedaquiline: a systematic review.
Jin Jie, Cao Jie, Zhang Ruoying et al. · Eur J Clin Pharmacol · 2025
PMID: 39779577Meta-Analysis
Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study.
Wang Ming, Men Peixuan, Zhang Weihe et al. · J Glob Antimicrob Resist · 2024
PMID: 38561143Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bedaquiline (substance)
SNOMED CT
714086004
UMLS CUI
C1664205
RxNorm CUI
1364504

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.